Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
Trappe
R
R
Riess
H
H
Anagnostopoulos
I
I
Neuhaus
R
R
Gärtner
B C
BC
Pohl
H
H
Müller
H P
HP
Jonas
S
S
Papp-Vary
M
M
Oertel
S
S
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007167:Immunotherapy; D016031:Liver Transplantation; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000821:virology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D000069283:Rituximab